FDMT's Quality Score fell 3 points on Tue, Nov 10, to -1. Its price broke out of a narrow range (3 chart checks stopped).
Follow FDMT's trial news. Pro members can get an alert when 4D Molecular Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 50% over five years while the S&P 500 rose 72%; up 23% in the past year.
| Latest filing | 10-Q, Aug 13 |
ReportExpected to report tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +2.1% on average. Past reports ›
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
5 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +2.1% on average, higher 3 of 4 times.
$431M in cash
Chief Legal Officer Scott Bizily sold 1,635 shares on Oct 16, under a planned sale. 14 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means
FDMT is #147 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 147 |
Expected to report Wed Nov 11, after the close (tomorrow).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in revenue was primarily due to the clinical trial cost sharing and reimbursement amounts from Otsuka.”
FDMT's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“This increase was primarily driven by execution of 4D-150 Phase 3 clinical trials in wet AMD.”
From its results filing (SEC filing · Aug 13)
Its share count grew 21% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 13, 2026 | -0.2% | +4.6% | +38.2% |
| May 7, 2026 | -8.6% | +2.1% | -1.2% |
| Mar 18, 2026 | +16.1% | +4.9% | +15.4% |
Sales grew in four of the last six years, to $85.2M in 2025. It lost money in each of the seven years.
RSI 50.1, MACD above signal, below its 50-day, above its 200-day. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: FDMT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
“We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.”
FDMT scores -1 today, which Breakaway calls Poor. It is #147 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 50% over five years while the S&P 500 rose 72%; up 23% in the past year. Shares: 25.6% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
FDMT scores -1 today, which Breakaway calls Poor (below zero). That is #147 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FDMT's -1.
Expected to report Wed Nov 11, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. FDMT closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.